» Articles » PMID: 38348613

Longitudinal Reduction in Brain Volume in Patients with Schizophrenia and Its Association with Cognitive Function

Abstract

Establishing a brain biomarker for schizophrenia is strongly desirable not only to support diagnosis by psychiatrists but also to help track the progressive changes in the brain over the course of the illness. A brain morphological signature of schizophrenia was reported in a recent study and is defined by clusters of brain regions with reduced volume in schizophrenia patients compared to healthy individuals. This signature was proven to be effective at differentiating patients with schizophrenia from healthy individuals, suggesting that it is a good candidate brain biomarker of schizophrenia. However, the longitudinal characteristics of this signature have remained unclear. In this study, we examined whether these changes occurred over time and whether they were associated with clinical outcomes. We found a significant change in the brain morphological signature in schizophrenia patients with more brain volume loss than the natural, age-related reduction in healthy individuals, suggesting that this change can capture a progressive morphological change in the brain. We further found a significant association between changes in the brain morphological signature and changes in the full-scale intelligence quotient (IQ). The patients with IQ improvement showed preserved brain morphological signatures, whereas the patients without IQ improvement showed progressive changes in the brain morphological signature, suggesting a link between potential recovery of intellectual abilities and the speed of brain pathology progression. We conclude that the brain morphological signature is a brain biomarker that can be used to evaluate progressive changes in the brain that are associated with cognitive impairment due to schizophrenia.

Citing Articles

Proposal for a Novel Classification of Patients With Enlarged Ventricles and Cognitive Impairment Based on Data-Driven Analysis of Neuroimaging Results in Patients With Psychiatric Disorders.

Yasuda Y, Ito S, Matsumoto J, Okada N, Onitsuka T, Ikeda M Neuropsychopharmacol Rep. 2025; 45(1):e70010.

PMID: 40011069 PMC: 11864853. DOI: 10.1002/npr2.70010.


Longitudinal reduction in brain volume in patients with schizophrenia and its association with cognitive function.

Yamazaki R, Matsumoto J, Ito S, Nemoto K, Fukunaga M, Hashimoto N Neuropsychopharmacol Rep. 2024; 44(1):206-215.

PMID: 38348613 PMC: 10932790. DOI: 10.1002/npr2.12423.

References
1.
Yasuda Y, Okada N, Nemoto K, Fukunaga M, Yamamori H, Ohi K . Brain morphological and functional features in cognitive subgroups of schizophrenia. Psychiatry Clin Neurosci. 2019; 74(3):191-203. PMC: 7065166. DOI: 10.1111/pcn.12963. View

2.
Yamazaki R, Matsumoto J, Ito S, Nemoto K, Fukunaga M, Hashimoto N . Longitudinal reduction in brain volume in patients with schizophrenia and its association with cognitive function. Neuropsychopharmacol Rep. 2024; 44(1):206-215. PMC: 10932790. DOI: 10.1002/npr2.12423. View

3.
Veijola J, Guo J, Moilanen J, Jaaskelainen E, Miettunen J, Kyllonen M . Longitudinal changes in total brain volume in schizophrenia: relation to symptom severity, cognition and antipsychotic medication. PLoS One. 2014; 9(7):e101689. PMC: 4103771. DOI: 10.1371/journal.pone.0101689. View

4.
Mesholam-Gately R, Giuliano A, Goff K, Faraone S, Seidman L . Neurocognition in first-episode schizophrenia: a meta-analytic review. Neuropsychology. 2009; 23(3):315-36. DOI: 10.1037/a0014708. View

5.
Kubota M, van Haren N, Haijma S, Schnack H, Cahn W, Hulshoff Pol H . Association of IQ Changes and Progressive Brain Changes in Patients With Schizophrenia. JAMA Psychiatry. 2015; 72(8):803-12. DOI: 10.1001/jamapsychiatry.2015.0712. View